WELTVERLAG

New York, New York (PRWEB) May 31, 2013

Cura

Schöne europa hotel Bilder:

Europa – most bombed hotel in the world?

Bild von ThisParticularGreg
This is the Europa Hotel in Belfast – with its claim as the most bombed hotel in the world. (As a reminder, Belfast is where a lot of the battle is between the Republicans (who want Northern Ireland as part of the Republic of Ireland – where it is situated) and the Unionists (who want Northern Ireland to be part of the UK – where it currently is).

Bilderberg Europa Hotel

Bild von anthonycramp
Bilderberg Europa Hotel in Scheviningen, Den Haag

New York, NY (PRWEB) May 03, 2013

CarHistory.us.org today released their picks of the most stylish and fuel efficient cars of 2013.

We exist to provide our customers with the best information possible about cars, so they can make informed decisions before they buy, a company spokesman said. With gas prices still very high, letting them know which ones will get the best mileage is important. But we know they also want to be driving the best looking car, so we have combined both elements into our list.

At the top of the list is the Honda Fit Ev, an electric vehicle.

It gets great gas mileage, particularly in the city, but also has great lines and a sporty feel to it, the spokesman says. While some vehicles get marginally better mileage, the tradeoff in style doesn’t make them worth it.

The full list is as follows:

Honda Fit EV
Nissan Leaf
Scion iQ EV
Tesla Model S
Ford Focus Electric
Toyota Prius Hybrid
Audi A3
Volkswagen Jetta SportsWagon
Chevrolet Spark
Honda CR-Z

The company also released their list of the worst five cars in terms of fuel economy.

These cars, in our opinion, are irresponsible to own if you are concerned at all about either your budget or your environment, the spokesman said. They burn gas like no tomorrow, when the technology exists for them to be considerably more fuel efficient.

The worst of the worst is the Bugatti Veyron.

There are cars out there that by some estimates are 10 times as fuel efficient as the Bugatti, the spokesman said. We are really hoping to bring more awareness to this issue.

The worst of the worst include:

Bugatti Veyron
Ferrari FF
Rolls-Royce Phantom Coupe
Bentley Mulsanne
Cadillac CTS Wagon

The company said their ratings were based on a variety of sources including Consumer Reports, the government’s fuel economy information, and their own experience with the different styles of cars.

About CarHistory.us.org:

CarHistory.us.org was created to provide public vehicle records to clients across North America. With thousands of requests processed each day, CarHistory.us.org continues to grow as a reputable customer service resource. Visit CarHistory.us.org to chat with a live representative, call 1-877-888-0889, or email manager(at)CarHistory(dot)us(dot)org with any questions or concerns.

Find More Chevrolet Press Releases

Geneva, Switzerland & Brussels, Belgium (PRWEB UK) 8 April 2013

Tech Tour and the International Venture Club announced today that the 2013 Healthtech Summit will be held on June 25-26, 2013. The first annual Healthtech Summit will be one of Tech Tours Vertical Summits to profile Europes 20 most dynamic companies to international investors with the theme, Crossing the chasm from start-up to a sustainable high growth business.”

Aris Constantinides, Founder and Investment Director of NBGI Ventures, will serve as Co-President of the Healthtech Summit and commented on the state of the industry in Europe and the particular choice of theme for this years event, The healthcare landscape is changing globally and on many levels: regulatory, economic, and technological. We chose the particular theme to this years summit as, amongst these strong winds of change, entrepreneurs are increasingly required to build their companies into real, sustainable and successful high growth businesses. Aside from highlighting Europes 20 most promising healthtech companies, this years Summit is aimed at helping entrepreneurs overcome these important challenges and thinking about building for the long-term.

Rudy Mareel, former CEO of Synthon and Co-President of the Healthtech Summit explained his vision and goals for the upcoming Summit saying, “Innovation is poised to play a greater role in the evolution of the healthcare market as demographic, regulatory and financial challenges play out. Yet, new product and services concepts often struggle to gain momentum in the larger institutions. Entrepreneurs, in contrast, have the freedom to develop ideas, but are faced with limited resources that can just as easily stifle their innovations. Thats why weve designed The Healthtech Summit as a space for young companies and resources to meet. We look forward to robust interaction between technology innovators, leaders of the various venture capital groups who invest in healthcare and key players from the industry.”

No charge to apply
No charge for selected companies to attend the event and present selection is merit only based
Companies are selected by an expert selection committee, according to their potential market impact
Selected companies will present to a group of 100+ global investment professionals, advisors and corporates.

Registration

Applicants can register for the Summit at http://www.healthtechsummit.eu

As part of the process applicants must submit a corporate presentation together with the registration form. The deadline for applications is May 15.

Selection Criteria

Applicants will be assessed on the uniqueness of their technology, the strength of their business model, vision, and capability to execute on the business plan and the quality and track record of their management. Submissions will be reviewed by the selection committee, which is comprised of senior business leaders from various backgrounds including venture capital, technology, research and economic promotion.

Rewards for Finalists

The selected 20 finalists will each have an opportunity to present their business plans to senior partners, vice presidents and CEOs from the global venture capital and technology industry, as well as service providers and academics. In addition, they will benefit from networking opportunities, local and international media exposure and potential opportunities to secure funding.

Previous Summit attendees included senior representatives of most major investment firms and corporates:

Addex, ARES Life Science, Auriga Partners, Baxter International, Bay City Capital, BioBay, Biosensors, Boston Scientific, CDC Innovation, Creathor Venture, Credit Agricole Private Equity, Credit Suisse, Cukierman & Co. Life Sciences, Decheng Capital, Delta Partners, DFJ Esprit, Earlybird Venture Capital, Edwards Life Science, EIF, Endeavour Vision, Eurofin Ventures, Entrepreneurs Fund Management, EPFL, EuroUS Ventures, Fountain, Healthcare Partners, Gilde Healthcare Partners, GIMV, Go4Ventures, Index Ventures, Inventure Capital, Johnson & Johnson, Kreos Capital, Linde Healthcare, Medtronic, MVM Life Science Partners, NASA, NeoMed, Novartis Ventures, Polytech Ventures, Rothschild Group, Scottish Equity Partners, Siemens, Sofimac Partners Investment Capital, Sofinnova, Sony, Stryker, Trigon Medical, Valtronic Technologies, Wellington Partners.

Companies that have presented in previous Summits have either been acquired or raised more than $ 1 Billion in funding. Some notable examples can be found at http://www.iventureclub.com/events/view.aspx?events_pages_id=1764.

About the Tech Tour

The Tech Tour was founded in Geneva in 1998 in response to the growing interest in emerging technology companies in various European regions. The Tech Tour is an independent, not-for-profit organization composed of key contributors to the high technology industry. The organization recognizes that continued prosperity in Europe lies in its ability to transform today’s innovative projects into tomorrow’s global technology leaders.

http://www.techtour.com

About the International Venture Club

The International Venture Club was founded in 2011 as the collaborative platform of leading venture investors promoting successful international investments. Its objectives are to 1) share better practices, 2) build co-investor trust and relations, 3) foster new funding and investment opportunities through joint actions and PR, 4) grow promising companies with corporate partners and co-investors and 5) keep a smart window and support to emerging innovative companies.

http://www.iventureclub.com

Media Contacts:

Tanja Baltus

Europe Unlimited

+3-202-643-3694

tanja(at)e-unlimited(dot)com

Jaimie Guerra

Tech Tour

+4-122-544-6062

jaimie(at)techtour(dot)com

Montreal (PRWEB) February 20, 2013

With the Oscars just a few days away Digititles.com is presenting its picks for most glaring errors among this years nine Best Motion Picture nominees. Out of 210 mistakes spotted by viewers, Quentin Tarantinos Django Unchained led the pack with 54, followed closely by Ben Afflecks CIA thriller ARGO with 44 known errors. Only German director Michael Haneke, famous for his attention to detail, managed to keep his romantic drama Amour mistake-free.

Digititles.com highlights some of the mistakes from this years Best Motion Picture nominees:

*Django Unchained

Destin, FL (PRWEB) February 08, 2013

Chef Jekyll, a personal culinary chef in Destin specializing in small dinner parties and special occasions, is offering a fun list of the top ten most romantic meals for Valentines Day.

10) Hot dogs and smores, roasted on a stick over an open campfire.

9) A thick, juicy cheeseburger, onion rings, with a chocolate milk shake.

8) Pizza with lots of stringy, melted cheese and a good, red table wine.

7) Roasted Rack of Lamb and potatoes.

6) Spaghetti and Meatballs but only in a Disney movie.

5) Petite Filet Mignon and Lobster.

4) King Crab Legs, with drawn butter and lemon remember Flashdance.

3) Chilean Sea Bass with roasted red bliss potatoes.

2) Anything, as long as it is on a picnic blanket, way out in the woods, overlooking a lake (this is the everything tastes better on an outdoors picnic theory).

1) Champagne and chocolate-dipped strawberries (or even popcorn and wine) under a blanket by the fireplace. Because being with the one you love is the most important thing.

On Valentines Day, Chef Jekyll will be presenting a Romantic Dinner for Two for a couple who live in Niceville, FL. Their menu includes Lobster Cakes with Champagne Butter Sauce, Jekylls Compass Rose Salad, Grouper Piccata with Baby Red Potatoes, Roasted Asparagus with Asiago and Toasted Almonds, and Key Lime Pie, all served with a bottle of sparkling wine.

Chef Jekyll provides gourmet meals cooked from the comfort of his clients own homes. Private dinners and romantic evenings for two are his specialty. For information on planning a special dinner, and to see the menu options available, please visit: http://www.chefjekyll.com.

About the company:

Proprietor and Emerald Coast native son Carey Stegall better known as Chef Jekyll is a licensed private chef specializing in Local Seafood, Italian, and Southern Comfort cuisines. His clients include private individuals, businesses and families in Destin and throughout the Emerald Coast region of Northwest Florida. Returning to Destin, Florida in 2011 after his career in the military, Chef Jekyll has cultivated the local roots that were planted here 35 years ago among the emerald seas and white sands. Inspired by his travels around the world and residence on three continents, this newly established entrepreneur has honed his culinary skills to a fine edge. Chef Jekyll also offers cooking demonstration parties, as a fun alternative to traditional cooking classes. For more information, please visit the website.

More Gourmet Dinner Press Releases

Washington, D.C. (PRWEB) March 01, 2012

The ALS Association and the Robert Packard Center for ALS Research at Johns Hopkins have entered into a partnership to expedite the development of animal model systems to expand the knowledge about the C9ORF72 gene, which has been identified as the most common cause of inherited amyotrophic lateral sclerosis (ALS or Lou Gehrigs Disease) and Frontotemporal dementia (FTD).

The Association is very pleased to partner with the Packard Center to expedite these important studies, said ALS Association Chief Scientist Lucie Bruijn, Ph.D. The Association along with the Packard Center have both invested significant funds into the identification of this new gene, and we are pleased to be able to work together to support the critical next steps to ensure that possible discoveries from these projects are translated as rapidly as possible into therapies for ALS.

In October 2011, a large expansion of a hexanucleotide GGGGCC repeat was discovered in the C9ORF72 gene, but how the expansion causes malfunction of the nerve cells in ALS and FTD remains unknown. It is thought that the messenger RNA (mRNA) derived from this large repeat aberrantly accumulates. This scenario is reminiscent of what is known in other diseases caused by expanded repeats, especially myotonic dystrophy.

Building on that example and in partnership with Isis Pharmaceuticals, the Cleveland Laboratory in San Diego, Calif., has designed a gene silencing approach to develop a drug called an antisense oligonucleotide (ASO) that will selectively destroy the ALS-causing mRNA with the expanded repeat. Essential for drug development is a mouse model expressing the expanded human C9ORF72 mRNA. The investigators will build these models and use them to validate efficacy of the ASO drug. This research was funded by ALS Association California Chapters through a state program that allows taxpayers to direct donations toward the ALS/Lou Gehrigs Disease Fund when completing state tax forms.

Following the discovery of the most abundant genetic cause of ALS, we have initiated a drug development approach to selectively destroy the ALS-causing product of the mutated gene, said Don W. Cleveland, Ph.D., Departmental Chair of Cellular and Molecular Medicine, University of California San Diego. The ALS Association partnership with the Packard Center will fund development of a mouse model that genetically mimics the human gene mutation, which will represent an essential tool for validating drug development.

A parallel effort to inactivate the toxic C9orf 72 gene and identify drug activity biomarkers in ALS patients is also underway at the Packard Center with Bryan J. Traynor, M.D., of the Laboratory of Neurogenetics, National Institute on Aging and Johns Hopkins University and Jeff Rothstein, M.D., Ph.D., the Packard Center director.

Our partnership with The ALS Association provides a fantastic opportunity to quickly follow up on the identification of C9ORF72 by Packard and ALS Association Investigators and rapidly provide the ALS community with the essential tools to study the disease and develop much needed therapies. We are pleased to join forces-once again-to collaborate on this critical project, notes Packard Center Scientific Director Piera Pasinelli, Ph.D.

In addition, the mouse model may develop an ALS-like disease, which can be used to determine exactly what goes wrong in the presence of the aberrant mRNA. Complementary mouse models will be generated by a group of researchers from Johns Hopkins, which will focus on developing tools to understand the mechanisms resulting from the abnormally expanded repeats on C9ORF72 and point to new directions for the treatment of this devastating disease.

I believe that this unique joint funding from The ALS Association and Packard Center will be critical for initiating studies to clarify how hexanucleotide repeat expansion in C9ORF72 causes neurodegeneration in ALS-FTD, and these efforts will impact the design of appropriate therapy for patients, said lead researcher Philip C. Wong, Ph.D., Johns Hopkins School of Medicine Departments of Pathology and Neuroscience

Initially, Dr. Wong and his colleagues plan to develop mouse model systems to find out if losing C9ORF72 gene activity is responsible for death of motor neurons. Secondly, they hope to learn whether toxicity arises through the presence of a toxic RNA derived from the diseased C9ORF72 gene that determines malfunction of motor nerve cells.

Outcomes from these studies will clarify how hexanucleotide repeat expansion in the C9ORF72 gene causes motor nerve cell loss in a large proportion of cases of ALS. In addition, these efforts will have important implications for therapy design and provide useful mouse model systems for testing therapies that could eventually benefit people with ALS.

The mouse models developed through this initiative will be made rapidly available to researchers through the ALS Mouse Repository at Jackson Laboratories funded by a partnership with The ALS Association, Tow Foundation and ALS Therapy Alliance. Visit http://www.alsa.org/news/archive/tow-foundation-challenge.html for more information.

The discovery of the C9ORF72 genetic repeat, made by Dr. Bryan Traynor was funded by The ALS Association and the Packard Center. Another study reported at the same time with similar findings was led by Rosa Rademakers, Ph.D., Mayo Clinic; this study was also funded by The ALS Association. For additional information about the C9ORF72 studies visit http://web.alsa.org/site/PageNavigator/research_update_9_21_11.html and http://www.alscenter.org/news/rss_from_the_packard_center/11_09_21.html.

About The ALS Association

The ALS Association is the only national non-profit organization fighting Lou Gehrigs Disease on every front. By leading the way in global research, providing assistance for people with ALS through a nationwide network of chapters, coordinating multidisciplinary care through certified clinical care centers, and fostering government partnerships, The Association builds hope and enhances quality of life while aggressively searching for new treatments and a cure. For more information about The ALS Association, visit our website at http://www.alsa.org.

About the Robert Packard Center

Located in Baltimore, the Robert Packard Center for ALS Research at Johns Hopkins is a worldwide collaboration of scientists aimed at developing therapies and a cure for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrigs disease. The Center is the only international institution of its kind dedicated solely to the disease. Its research is meant to translate rapidly from the lab bench to the clinic, largely by eliminating time spent waiting for grants and lowering institutional barriers to sharing scientific results. Scientists and clinician members of the Packard Center have moved drugs reliably and rapidly from preclinical experiments to human trials. For more information about the Packard Center, visit our website at http://www.alscenter.org.

ALS is a progressive, disabling neuromuscular disease that causes complete paralysis and loss of function including the ability to eat, speak and breathe. ALS progresses quickly and is not curable. Most patients die within two to five years of diagnosis.

Contact: Greg Cash, The ALS Association Communications Director at gcash@alsa-national.org or 626-833-6711 or Suzanne Connelly, The Robert Packard Center for ALS Research at Johns Hopkins at sconnel6@jhmi.edu or 443-564-0977.

###

Related Orf News Press Releases